Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza białaczki limfocytowej
- •Wcześniejsze leczenie zanubrutinibem przez co najmniej 28 dni
- •Potrzeba rozpoczęcia następnej linii leczenia - болезнь nie ustąpiła po poprzedniej terapii lub szybko się pogarsza
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia oceniony na 0-2 w skali ECOG (pacjent może wykonywać większość zwykłych czynności)
- •Wystarczająca liczba komórek krwi (neutrofili, płytek krwi i hemoglobiny)
- •Prawidłowa funkcja wątroby
- •Prawidłowa funkcja nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Peter MacCallum Cancer Centre
Melbourne, Australia
Alfred Hospital
Melbourne, Australia
Monash Medical Centre
Melbourne, Australia
Trial contact
John F Seymour
Constantine Tam
Stephen Opat
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.